Sponsored by Agios Pharmaceuticals, Inc.
For US
audiences only

AQVESME significantly increases hemoglobin (Hb) in non-transfusion-dependent thalassemia*

AQVESME significantly reduces fatigue in non-transfusion-dependent thalassemia^†

AQVESME significantly reduces transfusion burden in transfusion-dependent thalassemia^‡

Talk to your doctor about AQVESME and whether it may be right for you.

ENERGIZE is a randomized, double-blind, placebo-controlled, phase 3 clinical trial in participants with NTD α- or β-thalassemia (N=194), that demonstrated 42.3% of participants on AQVESME achieved an Hb response (≥1 g/dL increase from baseline in average Hb from week 12 through week 24) vs 1.6% of participants on placebo (P<0.0001).¹˒²

^†In ENERGIZE, participants on AQVESME achieved a 4.85-point increase from baseline in average FACIT-Fatigue (Functional Assessment of Chronic Illness Therapy-Fatigue Scale) score from week 12 through week 24 vs an average 1.46-point increase for participants on placebo (P=0.0026).¹

^‡ENERGIZE-T is a randomized, double-blind, placebo-controlled, phase 3 trial in participants with TD α- or β-thalassemia (N=285), that demonstrated 30.4% of participants on AQVESME achieved a transfusion reduction response (≥50% and ≥2-unit reduction in transfused red blood cell [RBC] units from baseline in any consecutive 12 weeks through week 48) vs 12.6% of participants on placebo (P=0.0003).¹˒³

References: 1. AQVESME. Prescribing Information. Agios Pharmaceuticals, Inc.; 2025. 2. Taher AT, Al-Samkari H, Aydinok Y, et al; ENERGIZE investigators. Mitapivat in adults with non-transfusion-dependent α-thalassemia or β-thalassemia (ENERGIZE): a phase 3, international, randomised, double-blind, placebo-controlled trial. Lancet. 2025;406(10498):33-42. doi:10.1016/S0140-6736(25)000635-X. 3. Cappellini MD, Sheth S, Taher AT, et al. ENERGIZE-T: a global, phase 3, double-blind, randomized, placebo-controlled study of mitapivat in adults with transfusion-dependent alpha- or beta-thalassemia. Blood. 2024;144(suppl 1):409-411. doi:10.1182/blood-2024-200867.

Learn more about AQVESME

Sign up to receive information and resources about AQVESME. You'll receive a free patient brochure, updates, educational event invites, and information on how you can connect with an Agios Clinical Educator (ACE) for one-on-one support.

I would like to receive promotional communications about AQVESME. Phreesia may share my information with Agios Pharmaceuticals, Inc. as described in the Consent to Share. I have reviewed and agree to the Consent to Share.

[an error occurred while processing this directive] [an error occurred while processing this directive] [an error occurred while processing this directive]